Monocytes and granulocytes

Monocytes and granulocytes are essential components of the innate immune system, originating from myeloid progenitor cells in the bone marrow (StatPearls, 2023). Monocytes circulate in the blood before migrating into tissues to become macrophages or dendritic cells, where they play roles in phagocytosis and antigen presentation (NIH, 2022). Granulocytes, including neutrophils, eosinophils, and basophils, are characterized by the presence of granules in their cytoplasm and are the first responders to infection and inflammation (British Society for Immunology, 2021). While these cell populations are critical for host defense, their dysregulation is central to the pathogenesis of various inflammatory, autoimmune, and hematologic disorders (Nature Reviews Immunology, 2019). In clinical pharmacology, these cells are often monitored as markers of drug safety, such as drug-induced neutropenia, or targeted indirectly through signaling pathways like CSF-1R or CXCR2 to modulate the immune environment (Journal of Hematology & Oncology, 2021). It should be noted that "Monocytes and granulocytes" refers to a broad category of cell types rather than a specific molecular target like a receptor or enzyme. Consequently, drugs interacting with these cells often do so by affecting their production, survival, or functional recruitment rather than binding to the cells as a single entity.

Other names

Myeloid cellsLeukocytesWhite blood cellsPhagocytes

Drugs targeting these cell populations typically act by stimulating myeloid progenitor proliferation and differentiation, inducing apoptosis through cytotoxic mechanisms, or inhibiting chemotactic recruitment to sites of inflammation.